Medical technology company Echo IQ Ltd (ASX:EIQ) has seen its share price rise more than 11% as clinical tests showed its Heart Failure AI system accurately detected heart failure in 86% of patients. Results of the two clinical tests – which were run in collaboration with St Vincent’s Institute of Medical Research and the University of Notre Dame in Fremantle – showed that if AI and clinical evaluation were combined, they could raise diagnostic accuracy to 97% among high-risk individuals. This achievement is a crucial step for Echo IQ, which will be using these results for its FDA application …